Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
-
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
-
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
-
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
-
Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for invalidation of Kymab’s US patents USPTO upholds a fifth Kymab patent covering Human Antibodies and...
-
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
-
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...